Oncology Central

Should risk-reducing surgery in women from hereditary breast ovarian cancer families be confined to removal of the fallopian tubes with ovarian conservation?


Cancers attributed to ovarian origin are relatively uncommon in the USA general population, accounting for only 2.6% of cancers in women [1]. Yet, this disease is responsible for 14.2% of the cancer deaths in American women [1]. Over 21,000 women are expected to be diagnosed in the USA with ovarian cancer during the next year [1].

When detected and treated in its earliest stage, those who may be diagnosed with ovarian cancer have relatively good prognosis for survival; however, the majority of ovarian cancers have not been diagnosed until quite advanced when the outlook for relapse-free survival has been gravely disappointing [1,2].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.